These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 33134417)

  • 1. Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients.
    Ulrich RJ; Troxel AB; Carmody E; Eapen J; Bäcker M; DeHovitz JA; Prasad PJ; Li Y; Delgado C; Jrada M; Robbins GA; Henderson B; Hrycko A; Delpachitra D; Raabe V; Austrian JS; Dubrovskaya Y; Mulligan MJ
    Open Forum Infect Dis; 2020 Oct; 7(10):ofaa446. PubMed ID: 33134417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.
    Martins-Filho PR; Ferreira LC; Heimfarth L; Araújo AAS; Quintans-Júnior LJ
    Lancet Reg Health Am; 2021 Oct; 2():100062. PubMed ID: 34485970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial.
    Johnston C; Brown ER; Stewart J; Karita HCS; Kissinger PJ; Dwyer J; Hosek S; Oyedele T; Paasche-Orlow MK; Paolino K; Heller KB; Leingang H; Haugen HS; Dong TQ; Bershteyn A; Sridhar AR; Poole J; Noseworthy PA; Ackerman MJ; Morrison S; Greninger AL; Huang ML; Jerome KR; Wener MH; Wald A; Schiffer JT; Celum C; Chu HY; Barnabas RV; Baeten JM;
    EClinicalMedicine; 2021 Mar; 33():100773. PubMed ID: 33681731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of hydroxychloroquine for treatment of mild SARS-CoV-2 infection and prevention of COVID-19 severity in pregnant and postpartum women: A randomized, double-blind, placebo-controlled trial.
    González R; Goncé A; Gil MDM; Mazarico E; Ferriols-Pérez E; Toro P; Llurba E; Saéz E; Rodríguez-Zambrano MÁ; García-Otero L; López M; Santacruz B; Román MÁ; Payà A; Alonso S; Cruz-Lemini M; Pons-Duran C; Herrera LB; Chen H; Bardají A; Quintó L; Menendez C;
    Acta Obstet Gynecol Scand; 2024 Mar; 103(3):602-610. PubMed ID: 38098221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.
    Satlin MJ; Goyal P; Magleby R; Maldarelli GA; Pham K; Kondo M; Schenck EJ; Rennert H; Westblade LF; Choi JJ; Safford MM; Gulick RM
    PLoS One; 2020; 15(7):e0236778. PubMed ID: 32701969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ).
    Naggie S; Milstone A; Castro M; Collins SP; Lakshmi S; Anderson DJ; Cahuayme-Zuniga L; Turner KB; Cohen LW; Currier J; Fraulo E; Friedland A; Garg J; George A; Mulder H; Olson RE; O'Brien EC; Rothman RL; Shenkman E; Shostak J; Woods CW; Anstrom KJ; Hernandez AF;
    Int J Infect Dis; 2023 Apr; 129():40-48. PubMed ID: 36682681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxychloroquine (HCQ) Treatment for Hospitalized Patients with COVID- 19.
    Tsanovska H; Simova I; Genov V; Kundurzhiev T; Krasnaliev J; Kornovski V; Dimitrov N; Vekov T
    Infect Disord Drug Targets; 2022; 22(6):e030322201650. PubMed ID: 35240966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial.
    Byakika-Kibwika P; Sekaggya-Wiltshire C; Semakula JR; Nakibuuka J; Musaazi J; Kayima J; Sendagire C; Meya D; Kirenga B; Nanzigu S; Kwizera A; Nakwagala F; Kisuule I; Wayengera M; Mwebesa HG; Kamya MR; Bazeyo W
    BMC Infect Dis; 2021 Dec; 21(1):1218. PubMed ID: 34872511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and Design of the COVID-19 Outpatient Prevention Evaluation (COPE - Coalition V) Randomized Clinical Trial: Hydroxychloroquine vs. Placebo in Non-Hospitalized Patients.
    Oliveira Junior HA; Ferri CP; Boszczowski I; Oliveira GBF; Cavalcanti AB; Rosa RG; Lopes RD; Azevedo LCP; Veiga VC; Berwanger O; Avezum Á
    Arq Bras Cardiol; 2022 Feb; 118(2):378-387. PubMed ID: 35262569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial.
    Rojas-Serrano J; Portillo-Vásquez AM; Thirion-Romero I; Vázquez-Pérez J; Mejía-Nepomuceno F; Ramírez-Venegas A; Pérez-Kawabe KM; Pérez-Padilla R
    PLoS One; 2022; 17(2):e0261980. PubMed ID: 35139097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RETRACTED: Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study.
    Abd-Elsalam S; Esmail ES; Khalaf M; Abdo EF; Medhat MA; Abd El Ghafar MS; Ahmed OA; Soliman S; Serangawy GN; Alboraie M
    Am J Trop Med Hyg; 2020 Oct; 103(4):1635-1639. PubMed ID: 32828135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study.
    McKinnon JE; Wang DD; Zervos M; Saval M; Marshall-Nightengale L; Kilgore P; Pabla P; Szandzik E; Maksimowicz-McKinnon K; O'Neill WW
    Int J Infect Dis; 2022 Mar; 116():167-173. PubMed ID: 34954095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease.
    Griese M; Kappler M; Stehling F; Schulze J; Baden W; Koerner-Rettberg C; Carlens J; Prenzel F; Nährlich L; Thalmeier A; Sebah D; Kronfeld K; Rock H; Ruckes C; ; Wetzke M; Seidl E; Schwerk N
    Orphanet J Rare Dis; 2022 Jul; 17(1):289. PubMed ID: 35871071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.